That's true about Annovis only having 15 employees as of a year ago. They have added a few more full time employees (including a fulltime CFO)...so I think they're closer to 20 employees now.
But let's get serious here...employing a large number of employees doesn't guarantee success in biotech. On the contrary, the added financial obligations of paying huge salaries, paid vacations and other benefits will burden the company with more debt.
You have to balance the size of your staff with the expectations of your drug's position in the regulatory process. The closer you get to approval, the more you expand your staff accordingly.
Annovis has done an excellent job conducting several P1s, P2s, and P3s for PDD and AD. They are now expanding their staff because they are getting closer to FDA approval.
IMO, Anavex needs to focus on the CHMP rapporteurs...because they're opinion is the key to swaying the EMA voters to a positive vote.
abe
Market Data 
Markets 
AI
